Skip to main content

Drug Interactions between Hivid and Valcyte

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

zalcitabine valGANciclovir

Applies to: Hivid (zalcitabine) and Valcyte (valganciclovir)

The coadministration of ganciclovir or its prodrug, valganciclovir, with zalcitabine may result in elevated plasma concentrations of ganciclovir. In 10 asymptomatic subjects with HIV and CMV coinfection, zalcitabine (0.75 mg orally every 8 hours) increased the peak plasma concentration and area under the concentration-time curve of ganciclovir (1000 mg orally every 8 hours) by an average of 22% and 18%, respectively, although only the former was statistically significant. The mechanism is unknown. Ganciclovir had minimal effect on the pharmacokinetics of zalcitabine. This interaction is unlikely to be of clinical significance.

References

  1. Jung D, AbdelHameed MH, Teitelbaum P, Dorr A, Griffy K (1999) "The pharmacokinetics and safety profile of oral ganciclovir combined with zalcitabine or stavudine in asymptomatic HIV- and CMV-seropositive patients." J Clin Pharmacol, 39, p. 505-12
  2. (2001) "Product Information. Valcyte (valganciclovir)." Roche Laboratories

Switch to consumer interaction data

Drug and food interactions

Moderate

valGANciclovir food

Applies to: Valcyte (valganciclovir)

ADJUST DOSING INTERVAL: Food increases the bioavailability of ganciclovir from the prodrug, valganciclovir. In 16 HIV-positive subjects, the administration of valganciclovir 875 mg once daily with a high-fat meal containing approximately 600 calories resulted in a 30% increase in the steady-state area under the plasma concentration-time curve (AUC) and a 14% increase in the peak plasma concentration (Cmax) of ganciclovir, with no delay in the time to reach peak plasma concentration (Tmax). The mechanism is unknown.

MANAGEMENT: The manufacturer recommends that valganciclovir be taken with meals.

References

  1. (2001) "Product Information. Valcyte (valganciclovir)." Roche Laboratories
  2. Brown F, Banken L, Saywell K, Arum I (1999) "Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositiv volunteers." Clin Pharmacokinet, 37, p. 167-76

Switch to consumer interaction data

Minor

zalcitabine food

Applies to: Hivid (zalcitabine)

Zalcitabine bioavailability may be decreased by 14% if taken with meals. The mechanism and clinical significance are unknown.

References

  1. (2001) "Product Information. HIVID (zalcitabine)." Roche Laboratories

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer